Results 211 to 220 of about 1,924,532 (299)

Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
PCSK9 upregulation in cerebrovascular endothelial cells and microglia destabilizes the Aβ transporter LRP1, while TRIB3‐associated autophagy blockade further limits intracellular Aβ degradation. A RAP‐modified tea‐polyphenol nanoparticle co‐delivers siPCSK9 and siTRIB3 to restore LRP1‐mediated Aβ efflux and autophagy‐dependent degradation, reducing Aβ ...
Jie Miao   +8 more
wiley   +1 more source

Glutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors

open access: yesAdvanced Science, EarlyView.
An injectable bimodal TCPD nanodepot disrupts glutaminolysis and TCA metabolism, sensitizing large tumors to spatially complementary sono‐thermal ablation for complete treatment coverage. This intervention induces mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD+ depletion, converging to trigger PANoptosome assembly and ...
Yi‐Ming Liu   +10 more
wiley   +1 more source

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes. [PDF]

open access: yesNeurology
Shir D   +10 more
europepmc   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab). [PDF]

open access: yesCancer Res Commun
Ninmer EK   +14 more
europepmc   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang   +8 more
wiley   +1 more source

MN•CS•IO System: Cross‐Species Study for HBB Function in High‐Altitude Hypoxia Adaptation

open access: yesAdvanced Science, EarlyView.
We developed an integrative mesh‐nanorod sorting, chitosan nanoparticle delivery, and intraosseous injection (MN•CS•IO) system to investigate HBB in high‐altitude hypoxia adaptation. Transplanting Tibetan animals' HBB‐modified Lin‐ cells into mice achieved 95.59% transfection efficiency and 8.15% HBB expression. High‐altitude HBB recipients upregulated
Wenqiao Hui   +18 more
wiley   +1 more source

Scientific synergy between prophylactic and therapeutic HIV vaccines-prevention and cure. [PDF]

open access: yesNPJ Vaccines
Maciel M   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy